AiCure
AiCure is a private healthcare AI company that sells the H.Code platform — using computer vision and predictive analytics to verify medication adherence and capture digital biomarkers in clinical trials — to pharmaceutical, biotech, and CRO customers across 46 countries, with 7 of the top 10 global pharma as customers.
- Company typePrivate
- Founded2010
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What AiCure does
AiCure (legal entity AICure Corporation) is a New York-domiciled, private healthcare AI company founded in 2009/2010 that built H.Code, the first AI-powered medication adherence verification platform for clinical trials. H.Code uses proprietary computer vision, predictive analytics, and behavioral digital biomarker capture — via smartphone only, with no wearables or invasive hardware — to verify that the right patient takes the right medication at the right time, and to predict early termination risk (the first 14 days of adherence data are predictive of study completion). The platform is deployed across 2,200+ clinical trial sites in 46 countries and 45 languages, has captured 1.5M+ participant doses across 223+ studies spanning 15+ therapeutic areas, and serves 7 of the top 10 global pharmaceutical companies. Revenue is generated through quote-based, multi-year enterprise SaaS subscriptions to pharmaceutical, biotechnology, and CRO customers, supplemented by Clinical Site Services (CSS) professional services revenue. Go-to-market combines direct enterprise field sales (Account Directors at $145K-$165K), inside sales (SDRs), and a formal CRO channel program (AiPEX) with partners including Science 37, Qwince (Italy), OncoBay, IMA Group, and Recognify. The company holds 84 awarded patents (30 pending) and is compliant with 21 CFR Part 11, HIPAA, GDPR, SOC 2 Type 2, and ISO 27001. Following a leadership transition in May 2025 (Sabina Chadha appointed CEO; Ed Ikeguchi moved to CMO; Josh Wilson promoted to COO/President), AiCure was acquired by Vive VC, a healthcare-focused investment firm.
AiCure firmographics
Firmographics- Name
- AiCure
- Legal name
- AICure Corporation
- Website
- https://aicure.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- AiCure is a private healthcare AI company that sells the H.Code platform — using computer vision and predictive analytics to verify medication adherence and capture digital biomarkers in clinical trials — to pharmaceutical, biotech, and CRO customers across 46 countries, with 7 of the top 10 global pharma as customers.
- Ownership category
- akta.pro rank
AiCure industry classification
Industry- Product category
- Clinical Trial Technology / Digital Health AI
- NAICS
- Software Publishers (513210), Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Adherence, Reminders & Engagement Automation (Medication/Follow-up) (HLACAEAJ)
- akta.pro secondary industries
- ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history) (HLALAIAD), Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support) (HLACAIAG)
Keywords
Where AiCure is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
AiCure business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- AI-Powered Medication Adherence Platform (H.Code): SaaS platform subscription model providing medication adherence verification, patient engagement, and digital biomarker capabilities to pharmaceutical companies, biotech firms, and CROs for clinical trials. Revenue generated through platform licensing, implementation services, and ongoing support.
- Clinical Site Services: End-to-end clinical site support services including monitoring of adherence metrics, compliance tracking, and data management support for clinical trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise platform licensing for pharmaceutical companies and CROs |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
AiCure product offering
Product offeringCore offering
AiCure builds and licenses H.Code, an AI-powered medication adherence verification and patient engagement platform for clinical trials, using computer vision, synchronous chat, and predictive analytics on a smartphone to confirm that the right patient takes the right medication at the right time. The platform also captures digital biomarkers, supports eCOA/ePRO, and is complemented by Clinical Site Services for site monitoring, generating revenue primarily through multi-year enterprise SaaS subscriptions plus professional services for pharmaceutical, biotech, and CRO customers.
Product overview
AiCure offers H.Code, an AI-powered patient engagement and medication adherence verification platform for life sciences. The platform consists of multiple integrated modules: Patient Connect for medication reminders and engagement, Digital Phenotypes for capturing digital biomarkers, Site Services for clinical site support, AiCurator for data management, Clinical Site Dashboards for performance visibility, and eCOA/ePRO for patient-reported outcomes. The platform uses computer vision and predictive analytics to verify medication adherence and predict trial outcomes through smartphone-based observation.
Differentiator
Problem solved
Functional benefit
Brands
- H.Code: AI-powered patient engagement and adherence verification platform trusted by pharma, CROs, and providers to verify medication and clinical behavior adherence.
- Patient Connect
- AiCurator
- Digital Phenotypes
- OpenDBM
Products and services
- H.Code Platform AI-powered patient engagement and medication adherence verification platform that uses computer vision, synchronous chat, and predictive analytics through a smartphone to verify that the right patient takes the right medication at the right time, capture digital biomarkers, support eCOA/ePRO, and predict early termination risk across site-based, decentralized, fully virtual, and hybrid clinical trials. Sold to pharmaceutical sponsors, biotech firms, CROs, and clinical trial sites globally.
- Clinical Site Services (CSS) Professional services offering providing clinical trial sites with end-to-end, customized support and monitoring of adherence, compliance, data management, and technology-use metrics, delivering actionable data-driven guidance and contributing to early termination rates as low as 7.8% across 28 Phase I-IV studies with over 4,000 patients.
- OpenDBM (Open Digital Biomarker Platform) Open-source platform that allows researchers to apply AiCure's digital biomarker algorithms to their own datasets, supporting academic and translational research use cases for digital phenotyping and behavioral biomarker development.
Quantifiable outcome
- 92% participant retention rate
- +5 more outcomes
Companies that use AiCure
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
AiCure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature8 records
AiCure partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and regional.
- Defense Health Agency (DHA)coreDHA PTSD-DT Program deploying AiCure's AI platform in PTSD adaptive platform trial to simultaneously evaluate efficacy of multiple PTSD treatments in active service members and veterans. AiCure provides medication adherence platform and digital biomarker solution.
- QwinceregionalItaly-based technology and services company focused on helping organizations implement innovative solutions and advance healthcare. Partnership aims to foster clinical and commercial opportunities for deployment of AiCure's AI platform with pharmaceutical sponsors and government healthcare departments in Italy.
- The IMA GroupregionalPartnership to optimize clinical trial recruitment and patient engagement through combined expertise in patient recruitment and AI-powered adherence monitoring.
- OncoBay ClinicalregionalPartnership to improve oncology clinical trials and patient care through integration of AiCure's patient engagement and adherence verification with OncoBay's oncology-focused clinical services.
- Science 37corePartnership to enhance virtual clinical trials by integrating AiCure's medication adherence and patient engagement technology with Science 37's decentralized clinical trial platform.
- Recognify Life SciencesregionalPartnership using AiCure medication adherence technology for cognitive deficit studies. Recognify focuses on mental health and cognitive therapeutic areas with innovative approaches to improving medication adherence.
- MerckcorePartnership selected as finalist for 2021 Citeline Award for Best Use of AI in Clinical Trials. Collaboration on AI-powered clinical trial optimization.
- Various CRO Partners (AiPEX)coreAiPEX (AiCure Partnerships for Excellence) is a formal CRO partnership program enabling partners to leverage AiCure's platform of Medication Adherence and Predictive Insights, Digital Biomarkers, and ePRO products to offer higher quality data and robust insights for faster and smaller clinical trials.
Scale indicators12 records
Recent moves8 records
Expansion highlights6 records
AiCure competitors and assessment
Company assessmentBroad incumbents
- Medidata Solutions: Medidata (a Dassault Systèmes company) is a leading eClinical platform offering EDC, eCOA/ePRO, CTMS, and patient engagement tools. It directly competes with AiCure's H.Code in eCOA and patient engagement modules and is a more established suite for pharma sponsors.
- Veeva Systems: Veeva's Vault Clinical Suite covers CTMS, eTMF, and clinical operations, with ePRO and patient engagement capabilities. It targets the same large pharma customer base as AiCure and competes on platform breadth rather than AI depth.
- IQVIA: IQVIA combines CRO services with the Orchestrated Patient Engagement suite and eCOA technology, serving large pharma sponsors. It is a broader incumbent competing against AiCure on patient engagement, adherence, and trial technology.
Direct peers
- Clario: Clario (formed from ERT and Bioclinica) provides eCOA, cardiac safety, imaging, and patient-centric clinical trial technology. It directly overlaps with AiCure's adherence and ePRO offerings for global pharma sponsors and CROs.
- Science 37: Science 37 is a decentralized clinical trial platform and an AiPEX partner of AiCure. It competes in the DCT space where AiCure also plays, though primarily as an integrated partner rather than a head-to-head rival on adherence.
- Medable: Medable provides a decentralized trial platform including eCOA, ePRO, telehealth, and patient engagement. It targets the same pharma and CRO buyers as AiCure with a broader DCT-focused suite.
- Biofourmis: Biofourmis applies AI and wearable/sensor data to clinical trial endpoints and post-market patient monitoring. It overlaps with AiCure's digital biomarker and predictive analytics capabilities, particularly in decentralized and post-approval settings.
- Castor: Castor is an eClinical platform offering EDC, ePRO, and DCT tools, including an AI assistant for protocol design. It targets the same pharma/biotech and CRO segments as AiCure with an emphasis on mid-market and academic trials.
- ObvioHealth: ObvioHealth is a DCT-focused CRO and technology provider with its own patient app and eCOA capabilities. It competes in the same adherence and patient engagement categories for global sponsors running decentralized studies.
- Thread Research: Thread Research provides a decentralized clinical trial platform with patient engagement and data capture tools for pharma sponsors. It competes with AiCure on DCT-enabled trial execution and remote data collection.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
AiCure social profiles
Digital presenceAiCure compliance and trust
Trust signalCompliance6 records
AiCure financial estimates
Financial estimateRevenue estimate
Valuation estimate
AiCure leadership team
Management profileNumber of profiles
Profiles12 records
AiCure funding detail
Funding detailFunding overview
Funding rounds6 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AiCure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AiCure
What does AiCure do?
AiCure builds and licenses H.Code, an AI-powered medication adherence verification and patient engagement platform for clinical trials, using computer vision, synchronous chat, and predictive analytics on a smartphone to confirm that the right patient takes the right medication at the right time. The platform also captures digital biomarkers, supports eCOA/ePRO, and is complemented by Clinical Site Services for site monitoring, generating revenue primarily through multi-year enterprise SaaS subscriptions plus professional services for pharmaceutical, biotech, and CRO customers.
Is AiCure a public or private company?
AiCure is a private company. It is classified as venture growth investor backed and is currently operating.
When was AiCure founded?
AiCure was founded in 2010. It employs 101 to 250 people.
Where is AiCure based?
AiCure is headquartered in New York, United States, in the North America region.
How does AiCure make money?
Two revenue lines are on record. AI-Powered Medication Adherence Platform (H.Code) is the primary driver. The others are clinical Site Services.
Who are AiCure's main competitors?
Broad incumbents on record are Medidata Solutions, Veeva Systems and IQVIA. Direct peers are Clario, Science 37, Medable, Biofourmis, Castor, ObvioHealth and Thread Research.
Does AiCure have an API?
No public API is recorded for AiCure.
What industry is AiCure in?
AiCure's product category is Clinical Trial Technology / Digital Health AI. Its primary akta.pro industry code is HLACAEAJ, Adherence, Reminders & Engagement Automation (Medication/Follow-up), with a secondary code of HLALAIAD, ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history). Its NAICS code is 513210 and its SIC code is 7372.